查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1530006

老年用藥市場規模、佔有率、趨勢分析報告：依治療藥物、疾病狀態、通路、地區、細分市場預測，2024-2030年

Geriatric Medicine Market Size, Share & Trends Analysis Report By Therapeutics (Analgesics, Antihypertensive, Statins, Proton Pump Inhibitors), By Condition, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

老年醫學市場的成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球老年醫學市場規模預計將達到2,600億美元，2024年至2030年複合年成長率為7.5%。

世界老年人口的成長是世界各地醫療保健產業和政府面臨的主要挑戰之一，但事實證明這對老年醫學市場來說是一個福音。

老年人群中各種目標疾病的盛行率上升、人口結構變化、生活方式相關風​​險因素的趨勢增加、以及新興經濟體獲得醫療保健和負擔得起的醫療保健的機會顯著下降，預計市場將出現高速成長。

在預測期內，老年族群中阿茲海默症盛行率的上升預計將成為老年藥物市場的重要動力。 2015年，阿茲海默症國際組織發布的估計顯示，約有4,700萬人患有失智症，而這一數字預計每20年就會增加一倍。此外，根據阿茲海默症協會發布的估計，美國540 萬美國中約有 520 萬（96.3%）年齡在 65 歲或以上。

為了緩解年齡、生活方式和經濟發展等人口變數不利變化以及與人口老化相關的疾病趨勢上升所帶來的擔憂，已開發地區不斷向發展部門分配大量資源，改善醫療實踐。

例如，美國、德國、英國和日本分別將GDP的17.1%、11.30%、9.10%和10.20%用於醫療保健支出，其中大部分資源用於開發新藥，新軟體的開發，居家醫療。

老年藥物市場報告亮點

  • 在治療類別中，2023年降血壓治療將佔20.2%的佔有率。這些用於治療高血壓和低血壓。市面上有各種抗高血壓藥物。
  • 2023年，北美以超過38.7%的銷售佔有率佔據老年用藥市場的主導地位，這得益於發達的社會和醫療部門、最新藥物的供應以及保險覆蓋範圍，這是因為有很多60歲以上的老年人。
  • 預計亞太地區將呈現最高成長率，2024 年至 2030 年複合年成長率將超過 9.1%。與已開發地區相比，亞太國家在目標疾病的經濟負擔、醫療保健可近性、健康保險以及公共和私人醫療支出比例等方面存在顯著差異。
  • 預計中國和印度等國家的老年人口將大幅增加，這一因素預計將在預測期內老年藥物市場呈現上升趨勢。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章全球老年醫學市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全球老年醫學市場分析工具
    • 波特的分析
    • PESTEL分析

第4章 全球老年用藥市場：治療藥物、估算及趨勢分析

  • 細分儀表板
  • 全球老年醫學市場：2023年及2030年治療藥物波動分析
  • 止痛藥
  • 抗高血壓藥
  • 他汀類藥物
  • 抗糖尿病藥
  • 質子幫浦抑制劑 (PPI)
  • 抗凝血物
  • 抗精神病藥
  • 其他

第5章全球老年用藥市場：病理、估計與趨勢分析

  • 細分儀表板
  • 全球老年醫學市場：2023年及2030年病理變化分析
  • 心血管疾病
  • 關節炎與骨骼健康
  • 神經系統疾病
  • 癌症
  • 糖尿病與代謝紊亂
  • 呼吸系統疾病
  • 其他

第6章 全球老年用藥市場：通路、估算與趨勢分析

  • 細分儀表板
  • 全球老年用藥市場：2023年及2030年通路波動分析
  • 醫院藥房
  • 零售藥房
  • 線上

第7章 全球老年用藥市場：區域估計與趨勢分析

  • 2023 年和 2030 年全球老年藥物市場佔有率（按地區），百萬美元
  • 北美洲
    • 2018-2030年北美老年醫學市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030 年歐洲老年藥物市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太地區老年醫學市場估計與預測
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018-2030 年拉丁美洲老年醫學市場估計與預測
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 2018-2030年中東和非洲老年醫學市場估計與預測
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • AbbVie Inc.
    • Johnson &Johnson Services, Inc.
    • Merck and Co., Inc.
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • GSK plc
    • Takeda Pharmaceutical Company Limited
簡介目錄
Product Code: 978-1-68038-887-9

Geriatric Medicine Market Growth & Trends:

The global geriatric medicine market size is expected to reach USD 260.0 billion by 2030, registering a CAGR of 7.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increase in the global geriatric population is one of the major challenges for the healthcare industry and the governments across the globe, however, it has proven to be a boon for the geriatric medicine market.

The high market growth is anticipated on account of the rising prevalence of various target diseases in the geriatric population, the demographic shift, the upward trend in lifestyle-related risk factors, and the significantly improved access to affordable healthcare as well as medicine across the developing and emerging economies.

The rising prevalence of the Alzheimer's disease in the geriatric population is expected to serve as a high impact rendering driver for the geriatric medicine market over the forecast period. In 2015, as per the estimates published by the Alzheimer's disease International, nearly 47 million people have dementia and this number is expected to double after every 20 years. Furthermore, as per the estimates published by The Alzheimer's Association, in the U.S., out of the 5.4 million Americans living with the disease, nearly 5.2 million or 96.3% are aged 65 and above.

In order to mitigate the concerns arising due to the unfavorable shift in the demographic variables such as age, lifestyle patterns, economic development, coupled with the upward shift in the disease trends associated with the geriatric population, the developed regions have consistently improved their healthcare practices by allocating high amount of resources towards the healthcare and social development sectors.

For instance, the U.S., Germany, the UK, and Japan allocate 17.1%, 11.30%,9.10%,10.20%, of their GDP respectively towards healthcare expenditure and majority of these resources are channelized towards developing new drugs, new software, and building technology platforms for hospitals and home health services.

Geriatric Medicine Market Report Highlights:

  • In the therapeutic category, antihypertensive therapeutics accounted for a share of 20.2% in 2023. These are used for treating high and low blood pressure. There are a variety of antihypertensive drugs available in the market.
  • In 2023, North America dominated the geriatric medicine market with a revenue share of over 38.7% owing to the presence of well-developed social and healthcare sectors, the availability of the latest medicine, and insurance coverage coupled with the presence of a large number of people aged above 60 years.
  • Asia Pacific region is anticipated to exhibit the maximum growth rate at a CAGR of over 9.1% from the year 2024 to 2030. In comparison with the developed regions, the economic burden of the target diseases, the access to healthcare, health insurance and the percentage of public and private healthcare expenditures vary significantly in the Asia Pacific countries.
  • The countries such as China and India are expected to witness a significant rise in the elderly population base and this factor in turn is expected to create an upward trend in the geriatric medicine market over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Geriatric Medicine Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Geriatric Medicine Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Geriatric Medicine Market: Therapeutics Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Geriatric Medicine Market: Therapeutics Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Analgesics
    • 4.3.1. Analgesics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Antihypertensive
    • 4.4.1. Antihypertensive Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Statins
    • 4.5.1. Statins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Antidiabetic
    • 4.6.1. Antidiabetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Proton Pump Inhibitors (PPI)
    • 4.7.1. Proton Pump Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Anticoagulant
    • 4.8.1. Anticoagulant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Antipsychotic
    • 4.9.1. Antipsychotic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Antidiabetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Geriatric Medicine Market: Condition Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Geriatric Medicine Market: Condition Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Cardiovascular Disease
    • 5.3.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Arthritis and Bone Health
    • 5.4.1. Arthritis and Bone Health Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Neurological Disorders
    • 5.5.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Diabetes and Metabolic Disorders
    • 5.7.1. Diabetes & Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Respiratory Diseases
    • 5.8.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Geriatric Medicine Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Geriatric Medicine Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online
    • 6.5.1. Online Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Geriatric Medicine Market: Regional Estimates & Trend Analysis

  • 7.1. Global Geriatric Medicine Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. AbbVie Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Johnson & Johnson Services, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Merck and Co., Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Pfizer, Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bristol-Myers Squibb Company
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Sanofi
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. GSK plc
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Takeda Pharmaceutical Company Limited
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives